Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirsevimab PK/Safety in Healthy Chinese Adults
NCT04840849Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Primary completion
- Nov 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Nirsevimab with Placebo (2 arms). Primary endpoints: Serum Concentrations of Nirsevimab at Day 151, Maximum Observed Serum Concentration at Day 151 and 2 more. Started Jun 2021; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04840849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840849.